Aberdeen Group plc boosted its holdings in shares of Praxis Precision Medicines by 143.5% during the second quarter. Get Praxis Precision Medicines alerts:Insider Buying and SellingIn other news, General Counsel Alex Nemiroff sold 25,130 shares of Praxis Precision Medicines stock in a transaction that occurred on Thursday, November 20th. On average, analysts predict that Praxis Precision Medicines, Inc. will post -10.22 EPS for the current year. Check Out Our Latest Stock Report on Praxis Precision MedicinesPraxis Precision Medicines Company Profile(Free Report)Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.